Drug Screening
Drug Screening - Related Videos
11:28
3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening
0 Views •
Cited by 7 •
2017
This protocol describes the fabrication of elastic 3D macroporous microcryogels by integrating microfabrication with cryogelation technology. Upon loading with cells, 3D microtissues are generated, which can be readily injected in vivo to facilitate regenerative therapy or assembled into arrays for in vitro high-throughput drug screening.
08:34
A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
0 Views •
Cited by 6 •
2015
A protocol for small molecular drug screening based on in-situ synthesis of ultrasmall fluorescent gold nanoclusters (Au NCs) using drug-loaded protein as template is presented. This method is simple to determine the binding affinity of drugs to a target protein by a visible fluorescent signal emitted from the protein-templated Au NCs.
03:17
Cellular Bioluminescence Based Assay: A High Throughput Method for Combinatorial Drug Screening
0 Views •
2023
In this video, we describe a method highlighting the utility of bioluminescence assay for sensitive and rapid screening of drugs. These drugs can be tested alone or in combination to assess the synergism in their mode of action.
05:54
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
0 Views •
Cited by 10 •
2018
Across a wide variety of disease indications, more physiologically relevant models are being developed and implemented into drug discovery programs. The new model system described here demonstrates how three-dimensional tumor spheroids can be cultured and screened in a high-throughput 1536-well plate-based system to search for new oncology drugs.
08:05
Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
0 Views •
Cited by 9 •
2012
We have developed a high-density microarray platform consisting of 3D nano-biofilms of C. albicans called CaBChip. The susceptibility profile of drugs tested on a CaBChip is comparable to the conventional 96-well plate model, suggesting that the fungal chip is ideally suited for true high-throughput screening of antifungal drugs.
FAQs
Researchers connect a compound’s biological effect to a potential neuroscience target by measuring outcomes such as target binding, neuronal signaling, synaptic activity, cell viability, or behavior. These readouts examine different levels of nervous-system function, so agreement between assays can strengthen interpretation, while discordant results may indicate that an apparent effect is indirect, selective for another process, or associated with toxicity.
They help distinguish a genuine compound-related effect from variation introduced by the assay or an unrelated condition. Testing across defined concentrations allows researchers to examine whether a response changes with dose and to identify a dose-response relationship. Controls provide the comparison needed to interpret neuronal signaling, synaptic activity, viability, or other measured outcomes consistently.
The distinction between primary and secondary screening reflects different stages of evidence. Primary assays can examine many compounds efficiently, whereas focused secondary tests revisit selected candidates to confirm dose-response behavior, selectivity, or toxicity. This progression reduces the number of compounds requiring detailed investigation and helps prioritize candidates for further preclinical or clinical study.
A positive primary result is not treated as final evidence. Researchers apply focused secondary tests to the selected compound, examining dose-response relationships and, where supported by the assay design, selectivity and toxicity. These follow-up measurements help determine whether the initial signal is reproducible and biologically informative enough to justify additional preclinical or clinical investigation.
Molecular assays can address target binding, cellular assays can measure neuronal signaling, synaptic activity, or viability, and organismal assays can measure behavior. Using these levels allows researchers to connect a compound’s action at a biological target with effects in cells or whole organisms, while also revealing where safety or interpretation questions require further testing.
In neuroscience, screening helps investigate mechanisms underlying nervous system function as well as identify candidates for neurological and psychiatric disorders. Measured effects on targets, neurons, synapses, viability, or behavior can reveal how compounds influence biological processes. The resulting evidence supports decisions about which candidates merit further preclinical or clinical investigation.